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In a pilot study, we evaluated the efficacy and the safety of cefepime, a new
cephalosporin with extended-spectrum activity against both Gram-positive and
Gram-negative bacteria, as empirical monotherapy for 108 febrile episodes in 84
granulocytopenic cancer patients. Cefepime (2 g tds) was given for a minimum of 7
days or until resolution of infection. Of the 108 episodes, 91 were evaluable.
Microbiologically documented infections occurred in 25 patients (27%) (18
Gram-positive, 7 Gram-negative), of whom 18 had bacteraemia. Infection was
clinically documented in 47 patients (52%) and fever was unexplained in 19 (21%).
Overall, 71% (65/91) of the infections resolved. Response rates were 86% (6/7) for
Gram-negative infections, 44% (8/18) for Gram-positive infections (57% for cefe-
pime-susceptible Gram-positive bacteria), 77% (36/47) for clinically documented
infections and 79% (15/19) for unexplained fevers. Of the 26 patients (29%) whose
primary infections did not improve with cefepime monotherapy, 23 responded after
the addition of other antibiotics. Sixteen patients (18%) developed secondary
infections of which 13 were microbiologically documented; Gram-positive bacteria
were isolated from seven patients, Gram-negative bacteria from two, fungi from
three and a virus from one. Adverse effects were mild and did not require premature
discontinuation of therapy except for one patient who developed an immediate
allergic reaction after the first dose of cefepime from which he recovered fully. The
survival rate after resolution of granulocytopenia was 96%; three patients died of
primary bacterial infection and one from secondary disseminated candidiasis.
In this pilot study, cefepime monotherapy appeared safe and effective as empirical
therapy for fever in cancer patients with granulocytopenia. Whether cefepime is
superior to other advanced-generation cephalosporins for the treatment of
Gram-positive infections will require evaluation in a larger comparative study.
Introduction
For many years, combinations of /Mactam antibiotics and aminoglycosides have been
standard therapy for suspected infections of bacterial aetiology in cancer patients with
granulocytopenia (Young, 1989; Calandra & Cometta, 1991). Recent studies have
shown that monotherapy with ceftazidime (Fainstein et ai, 1983; Pizzo el ai, 1986;
Deresinski, De Pauw & Feld, 1991) or imipenem-cilastatin (Winston eta/., 1991;
Rolston et al., 1992) was as effective overall as combination therapy for the empirical
treatment of such infections. However, combination therapy may still be the treatment
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of choice in high-risk patients, such as those with Gram-negative bacteraemia and
persistent or profound granulocytopenia (EORTC, 1987).
Currently, Gram-positive bacteria, especially coagulase-negative staphylococci and
viridans streptococci, have replaced Gram-negative bacilli as the predominant patho-
gens in the neutropenic host. Third-generation cephalosporins such as ceftazidime are
highly active against Gram-negative bacteria but are suboptimal treatment for infec-
tions caused by Gram-positive bacteria. Also, the extended-spectrum penicillins are not
active against /Mactamase-producing Gram-positive bacteria while, in general,
/Mactams are inactive against methicillin-resistant staphylococci. Therefore, vanco-
mycin or teicoplanin have been used empirically to improve the cover against
Gram-positive bacteria. However, four studies have now shown that glycopeptide
antibiotics need not be part of the initial antibiotic regimen in these patients (Rubin
et al., 1988; EORTC, 1991ft; Novakova, Donnelly & De Pauw, 1991; Ramphal et al.,
1992). Their use should be limited, therefore, to patients with suspected or confirmed
methicillin-resistant staphylococcal infections or with Gram-positive infections not
responding to specific therapy. The indiscriminate use of glycopeptide antibiotics might
otherwise result in the emergence of resistant staphylococci or enterococci, which
would be highly undesirable. Thus, other therapeutic options should be aimed at
improving the outcome of Gram-positive infections.
Cefepime is a new injectable cephalosporin with excellent activity against aerobic
Gram-negative and Gram-positive bacteria (Kessler et al., 1985; Dornbusch, Mortsell
& Goransson, 1990). MICs of cefepime and ceftazidime are similar for
Gram-negative bacteria including Pseudomonas aeruginosa. Against methicillin-
susceptible staphylococci and viridans streptococci, the MICs of cefepime are ten times
lower than those of ceftazidime and similar to those of vancomycin (Kessler et al.,
1985). Against 90 Gram-positive bacteria isolated from blood cultures at the Centre
Hospitalier Universitaire Vaudois (Lausanne, Switzerland), the MIC^s of cefepime
were 4 mg/L for methicillin-susceptible Staphylococcus aureus (n = 25), 2 mg/L for
methicillin-susceptible coagulase-negative staphylococci (n =19) , 1 mg/L for viridans
streptococci (n = 24) and 0-12 mg/L for /?-haemolytic streptococci (n = 22). The clinical
efficacy of cefepime has been evaluated in more than 500 mostly non-neutropenic
patients (data on file, Bristol-Myers Squibb & Co., Princeton, NJ, USA). Clinical and
bacteriological responses were respectively 95% and 88% for urinary tract infections,
95% and 82% for skin and soft tissue infections, and 94% and 88% for lower
respiratory tract infections (data on file, Bristol-Myers Squibb & Co., Princeton, NJ,
USA; Oster et al., 1990).
The purpose of this prospective pilot study was to investigate the efficacy and
tolerance of cefepime as empirical monotherapy for febrile episodes in granulocyto-
penic cancer patients. Clinical efficacy was evaluated according to three different
methods of assessment.
Material and methods
Patient selection
Patients were eligible for inclusion if they had cancer, granulocytopenia (defined as an
absolute granulocyte count of < I Ox IO9/L) and fever (defined as a temperature of
> 38-0°C on one occasion). Patients were not eligible if they were younger than 16
years of age, pregnant or nursing, had known hypersensitivity to jS-lactam antibiotics,
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had a serum creatinine > 300 /miol/L, had already been entered into the study during
the same episode of neutropenia or had received parenteral antibiotics < 4 days before
randomization. Patients receiving oral antibiotics for the prevention of bacterial
infection were eligible, provided the prophylaxis was stopped when iv antibiotics were
initiated.
The protocol was approved by the Ethics Committee of the two participating
institutions and the study was conducted in accordance with the Recommendations
Guiding Medical Doctors in Biomedical Research Involving Human Subjects (Helsinki
Declaration). All patients gave written or oral informed consent.
Initial and follow-up patient evaluation
At study entry and daily thereafter, a complete history was obtained from all patients
and they underwent a physical examination. The laboratory tests performed at random-
ization and at least twice-weekly during the study included determinations of haemo-
globin, haematocrit, WBC and differential count, platelet count, prothrombin time,
partial thromboplastin time, sodium, potassium, blood urea, serum creatinine, bili-
rubin, serum aspartate aminotransferase, serum alanine aminotransferase, alkaline
phosphatase and urinalysis. A chest X-ray, blood cultures (two sets, each from separate
venepunctures performed at 30 min intervals), urine specimens and specimens from any
clinically suspected site of infection were also obtained from all patients. In patients
with bacteraemia or with persistent fever, blood cultures were repeated daily until
resolution of infection.
Participating centres
The study was conducted at the Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland (68 patients enrolled) and at the Institut Jules Bordet, Brussels, Belgium
(40 patients enrolled). Eligible patients were enrolled consecutively in Lausanne; in
Brussels, consecutive eligible patients were randomized 1 : 4 to this study or to an
ongoing therapeutic study of the European Organization for Research and Treatment
of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group
(IATCG), respectively.
Antibiotic treatment
Two grams of cefepime (Bristol-Myers Squibb Co., Princeton, NJ, USA) were adminis-
tered three times daily. The antibiotic was reconstituted with sterile water for infusion,
mixed with between 50 and 100 mL of sodium chloride 0-9% and infused i.v. over a
30-min period. Cefepime was given for a minimum of 7 days or until resolution of all
signs and symptoms of infection, except in patients with a non-infectious fever in whom
therapy was discontinued after 4 days.
Classification of febrile episode
According to the definitions of the IATCG of the EORTC, primary febrile episodes
were classified as microbiologically documented infections with or without bacter-
aemia, clinically documented infections, unexplained fever (formerly designated as
possible infections) or non-infectious fever (i.e. fever associated with the underlying
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neoplasia or related to chemotherapy or to the transfusion of blood products)
(EORTC, 1991a). A bacteraemia was defined as the isolation of a pathogenic micro-
organism from one or more blood culture bottles. For coagulase-negative staphylo-
cocci, corynebacteria or other skin contaminants, two sets of positive blood cultures
were required, unless the same organism was isolated concomitantly from another
infected site.
Evaluation of response
The response to cefepime therapy was evaluated according to the definitions of the
IATCG of the EORTC (EORTC, 1991a). These results were compared with those
obtained using the definitions of Pizzo et al. (1986) and those of the
Immunocompromised Host Society (IHS) (1990).
The definitions used to assess the response to empirical therapy with cefepime in
evaluable patients were as follows:
(1) IATCG of the EORTC. Success was resolution of fever and all clinical signs of
infections (whenever present) and eradication of the infecting microorganism
(whenever isolated) without discontinuation of cefepime or addition of other anti-
bacterial agents; response must have been maintained for at least 4 days after
discontinuation of cefepime. Failure was either: death from primary infection; persist-
ence of bacteraemia beyond the first 24 h of therapy; breakthrough bacteraemia; or no
response to therapy (defined as the persistence of a pathogen and/or fever in a patient
whose condition was not improving and who required discontinuation of cefepime or
the addition of other antibacterial agents). The addition of antiviral or antifungal
agents without a concomitant change in the antibacterial therapy was not considered a
failure.
(2) Criteria of Pizzo et al. (1986). Success without modification referred to episodes in
which the patient successfully recovered from fever and neutropenia without the need
for the addition of antimicrobial agents or the modification of the initial, randomly
assigned regimen. Success with modification referred to episodes in which the patient
successfully recovered from the fever and neutropenia but required a modification of
the assigned regimen. Failure referred to death resulting from a documented or
presumed infection during the neutropenic episode.
(3) IHS. Success: all signs, symptoms, and microbiological evidence of infection had
resolved with the primary therapy. No recurrence of infection was found for at least 1
week after discontinuation of the initial antibacterial regimen. Initial response but
regimen modified (IRBRM): the initial pathogen was eradicated by the primary
regimen but a second infection/fever developed which fell outside the spectrum of the
primary antibacterial(s) and which required the addition of another antimicrobial agent
(e.g. antifungal, antiviral or antiparasitic). Failure: the addition to, modification of, or
change in the initial antibacterial regimen in order to eradicate the primary infection
resulted in the initial regimen being designated as having failed. Death due to infection
would also be classified as a failure. Non-response (applicable only to patients with
unexplained fever): the addition of a non-antibacterial antibiotic (e.g. antifungal,
antiviral or antiparasitic) for a specific indication or of an antibacterial agent because
of a new bacterial infection in a patient with unexplained fever who had not responed
(i.e. defervesced) to the initial antibacterial regimen caused the episode to be designated
a non-response.
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Further infections and death
Further infections were defined as new infections caused by an organism not recognized
as the initial pathogen and which occurred either during therapy or within 1 week after
discontinuation of therapy. Death was attributed to infection when it occurred as a
direct consequence of either the presenting or a further infection.
Toxicity
Hypokalaemia was defined as a fall in the serum potassium of ^ 0-5 /jmol/L in the
absence of gastrointestinal loss or treatment with another potassium-depleting drug.
Nephrotoxicity was defined as a rise in the serum creatinine of > 45 jxmol/L if the
baseline creatinine was ^ 260 /zmol/L or a rise of > 90 jjmol/L if the baseline
creatinine was > 260 //mol/L in the absence of other causes of renal dysfunction (e.g.
hypotension or hypovolaemia) or other potentially nephrotoxic drugs (e.g. cisplatin,
amphotericin B, acyclovir or vancomycin). Hepatotoxicity was defined as a two-fold
increase in bilirubin or serum aspartate aminotransferase and serum alanine amino-
transferase in the absence of other potentially hepatotoxic drugs or any other causes of
hepatic dysfunction.
Microbiology
Standardized identification and antibiotic susceptibility testing were used (Barry &
Thornsberry, 1991; Isenberg et al., 1991; Sahm & Washington, 1991). Susceptibility
data were evaluated according to the zone diameter interpretative standards and the
equivalent MICs recommended by the National Committee for Clinical Laboratory
Standards (NCCLS, \990a,b). An isolate was considered resistant to cefepime if the
MIC was > 32 mg/L or if the inhibitory zone diameter by the Kirby-Bauer method
was ^ 15 mm (data on file Bristol-Myers Squibb Co., Princeton, NJ, USA).
Results
Between January 1990 and May 1991, 108 febrile episodes in 84 granulocytopenic
cancer patients were entered into the trial. Fifteen patients who together accounted for
36 episodes of fever were included on multiple occasions, all during separate episodes
of neutropenia. For the remainder of this paper, the terms 'episodes' and 'patients' will
be used interchangeably.
Seventeen patients could not be evaluated for response to therapy for the following
reasons: a protocol violation in six patients (unjustified discontinuation of cefepime in
four and non-eligibility in two); a fever of non-infectious origin in six patients (fever
was due to cancer in five patients and to the infusion of granulocyte-macrophage
colony-stimulating factor (GM-CSF) in one); a non-bacterial infection in four patients
(herpes simplex stomatitis in three and pulmonary tuberculosis in one); and the
discontinuation of therapy because of an anaphylactic reaction in one patient.
Of the 91 evaluable patients, there were 48 males and 43 females with a mean age of
48 years (range 17-78). The underlying conditions were haematological malignancies in
57 patients (63%) and solid tumours in 34 patients (37%). Seven patients (8%) had
undergone allogeneic bone marrow transplantation.
156 P. Eggimann et al.
At study entry, patients had a median granulocyte count of O3xlO9/L (range
0-0-992 x 109/L)- Profound granulocytopenia (i.e. sj 01 x 109/L) was present in 64% of
patients. At the time of entry, patients had been granulocytopenic for a median of 6-5
days (range 0-65). The median duration of granulocytopenia while receiving therapy
was 8 days (range 1-35). Overall, 62% of the patient-trial days were spent with
granulocyte counts of ^ 01 x 109/L, 19% with counts between 0101 and 0-5 x 109, 7%
with counts between 0501 and 1-0 x 109/L and 12% with counts > 10 x 109/L.
Fifty-three patients (58%) had received oral antibacterial prophylaxis which
comprised a fluoroquinolone in 50 patients (pefloxacin 400 mg bd in 36, norfloxacin
400 mg bd in 13 and ciprofloxacin 250 mg bd in one); this was administered in
combination with penicillin V (500 mg bd) in ten patients. Erythromycin, spiramycin
and co-trimoxazole were given to one patient each. Oral antifungal prophylaxis was
given to 51 patients (56%) and included amphotericin B (100 mg 6 hourly) in 31 cases,
amphotericin B (500 mg qds) in seven, fluconazole (200 mg od) in four and itraconazole
(200 mg bd) in nine.
Details of the 91 evaluable febrile episodes are shown in Table I. Microbiologically
documented infections occurred in 25 patients (27%). Eighteen infections (72%) were
caused by Gram-positive bacteria and seven (28%) by Gram-negative bacteria.
Bacteraemia was detected in 18 patients; 15 of the episodes were caused by
Gram-positive bacteria. Fourteen of 18 (78%) Gram-positive pathogens and all of the
Gram-negative pathogens were susceptible to cefepime. The four Gram-positive
Table I. Documentation of infection in the 91 evaluable episodes
Type of infection
Microbiologically documented infections
with bacteraemia
without bacteraemia
Gram-positive bacterial pathogen
coagulase-negative staphylococci
streptococci
viridans streptococci
/Miaemolytic streptococci
S. pneumoniae
Staphylococcus aureus
other organisms"
Gram-negative bacterial pathogens
Pseudomonas aeruginosa
Escherichia coli
other*
Clinically documented infections
sites of infection
oral cavity and pharynx
lower respiratory tract
skin and soft tissues
gastrointestinal tract
Unexplained fever
No. of episodes
25 (27%)
18
7
18
8
5
3
1
1
3
2
7
2
2
3
47 (52%)
28
10
7
2
19(21%)
"One Clostridium sepiicum isolate and one Swmaiococcus mucilaginosus
isolate.
ftOne isolate each of Proteus vulgaris, a Leptolrichia sp. and Klebsiella
pneumoniae.
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Table II. Influence of antibacterial prophylaxis on the development of infection
Classification of infection
Number of patients
Microbiologically documented infection
Gram-positive infection
Gram-negative infection
Clinically documented infection
Unexplained fever
Administered
prophylaxis
53
10 (19%)
1 (2%)
32 (60%)
10 (19%)
Not administered
prophylaxis
38"
8(21%)*
6(16%)'
15(39%)''
9 (24%)"
Fisher's exact test (two-tailed): "P = 005: */» = 005; '/> = 002; dP = 006; 'P = 0-61.
bacteria resistant to cefepime included three coagulase-negative staphylococci causing
catheter-related infections and one isolate of Clostridium septicum which was respon-
sible for a fatal episode of septic shock. Only one of these four bacteria (a coagulase-
negative staphylococcus) was isolated from a patient who had previously been treated
with cefepime. The sites of these microbiologically documented infections were the skin
and soft tissues (ten patients, three of whom had catheter-related infections), the oral
cavity or upper respiratory tract (five patients), the lower respiratory tract (three
patients) and the gastrointestinal tract (one patient). In six patients the primary site of
infection could not be identified. Clinically documented infection occurred in 47
patients (52%); the most frequently implicated sites of infection were the oral cavity
and pharynx (60%). In 19 patients the cause of fever was unexplained.
As shown in Table II, the use of antibacterial prophylaxis had a significant impact on
the documentation of infection (P = 005). Gram-negative infections occurred more
often in patients who had not received antibacterial prophylaxis (16% vs 2%, P =
0-02), whereas clinically documented infections were more common in patients who had
received prophylaxis (60% vs 39%, P = 006). Of the 11 microbiologically documented
infections occurring in patients who received prophylaxis with fluoroquinolones, ten
were bacteraemias, eight of which were caused by organisms (three coagulase-negative
staphylococci, three viridans streptococci and one isolate each of Stomatococcus
mucilaginosus and a Leptotrichia sp.) resistant to the antibiotic used for prophylaxis.
The response rates of each category of infection to cefepime monotherapy are shown
in Table III. Response was evaluated according to the criteria of the IATCG of the
EORTC and the results were compared with those obtained with the other two
methods of assessment. Overall, 71% of infectious episodes responded to cefepime
alone. For microbiologically documented infections, clinically documented infections
and unexplained fevers, response rates were 56%, 77% and 79% respectively. Six of
seven (86%) Gram-negative infections, but only eight of 18 (44%) Gram-positive
infections, resolved with cefepime monotherapy. The response rate for Gram-positive
infections rose to 57% (8/14) when only Gram-positive bacteria which were susceptible
in vitro to cefepime were considered.
Of the ten Gram-positive infectious episodes which failed to respond, there were three
deaths which were attributed to the primary infections. Two patients died of septic
shock 24 h after the initiation of therapy; the pathogens were a cefepime-susceptible
strain of S. aureus and a cefepime-resistant Clostridium septicum isolate. The third
patient died on the seventh day of treatment from irreversible acute respiratory distress
syndrome (ARDS) associated with Streptococcus pneumoniae bacteraemia (susceptible
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to cefepime). Although this patient's granulocytopenia had resolved after only two
days of treatment, he remained febrile until his death. In two patients, failure was due
to persistence of fever and the development of ARDS 3 and 4 days after documentation
of bacteraemia caused by a cefepime-susceptible strain of Streptococcus mitis. Five
failures occurred in patients with coagulase-negative staphylococcal catheter infections.
Bacteraemia persisted during therapy in three patients, two of whom were infected with
cefepime-resistant strains. Another patient failed to respond because of non-bacter-
aemic infection caused by a cefepime-resistant bacterium. In the last patient, fever
persisted until modification of therapy and catheter removal. The only failure in
patients with Gram-negative infection was a catheter-related bacteraemic episode
caused by a cefepime-susceptible Leptotrichia sp. which was cured after removal of the
catheter and modification of therapy.
Thirty-six of 47 (77%) of the clinically documented infections were cured with
cefepime monotherapy. The reasons for failure included exacerbation of the infection
(five patients) or the persistence of fever and infection (six patients). Therapy was
modified after a mean of 6 days. In four patients with unexplained fever, antibiotic
therapy was changed after a mean of 6-5 days because the patient remained febrile.
When the data were analysed according to the guidelines of the
Immunocompromised Host Society, the response rates for each category of infection
were identical to those obtained with the EORTC criteria. Yet, 16 of 65 responders
(25%) developed secondary infections (see further infections below) which required
modifications of therapy. Therefore, these patients were classified as IRBRM.
Modifications of therapy included the administration of another antibacterial agent to
12 patients (additional to cefepime in six patients), acyclovir to two patients and
amphotericin B to one.
If success of therapy was defined as the survival of a patient who was free of infection
after resolution of granulocytopenia (see Pizzo's criteria), the overall response rate was
96% (87 of 91 patients). Response rates were 84% for microbiologically documented
infections and 100% for both clinically documented infections and unexplained fevers
(Table III). Forty-nine patients (54%) improved with cefepime monotherapy and
remained afebrile until resolution of granulocytopenia (success without modification).
Thirty-eight patients (42%) improved with modification of therapy (success with
modification) which cured either the primary infection (22 episodes) or secondary
infections (16 episodes) which developed in patients who had responded to the initial
cefepime monotherapy.
Secondary infections developed in 16 patients (18%). Of these, 13 were micro-
biologically documented and included seven episodes of septicaemia caused by Candida
albicans (two episodes), Streptococcus sanguis (one), Streptococcus salivarius (one),
Enterococcus faecalis (one), P. aeruginosa (one) and Bacteroides fragilis (one); only the
S. sanguis and 5. salivarius isolates were susceptible to cefepime. The non-bacteraemic
infections included Clostridium difficile colitis (three cases which occurred 5, 7 and 12
days respectively after initiation of cefepime therapy), S. aureus osteomyelitis (one
case), Aspergillus fumigatus pneumonia (one) and herpetic stomatitis (one). Proctitis
with ulceration and two episodes of unexplained fever accounted for the remaining
secondary infections. All but one of these infections occurred during episodes of
profound ( < 01 x 109/L) and persistent (mean 15 days; range 6-38) granulocytopenia,
mostly in patients with leukaemia. With the exception of one case of disseminated
candidiasis, all secondary infections were cured with appropriate therapy.
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All 108 patients who were entered into the study were evaluated for safety.
Abnormalities of liver function tests were noted in 13 patients (12%), of whom six had
received other potentially hepatotoxic agents. In all cases, liver dysfunction was mild
(the median increase in bilirubin or serum glutamic-oxaloacetic transaminase/serum
glutamic-pyruvic transaminase (SGOT/SGPT) concentrations was 2-3-fold, with a
range of 05- to 6-fold), did not require premature discontinuation of therapy and was
rapidly and fully reversible. Diarrhoea developed in four patients (4%). A minor rash
developed in six patients (6-5%) after 2 to 10 days of treatment. Nausea related to the
infusion of cefepime was noted in two patients. One patient developed generalized
urticaria after the first dose of cefepime; this was the only instance in which therapy was
discontinued prematurely because of toxicity.
Discussion
In this open study, we evaluated the efficacy of empirical monotherapy with cefepime, a
new advanced-generation cephalosporin with extended-spectrum activity against methi-
cillin-susceptible staphylococci and streptococci. As reported in many other recent
clinical trials, Gram-positive bacteria, particularly staphylococci and streptococci, were
the predominant pathogens (Cohen et al., 1983; EORTC, 1991a; Novakova et al.,
1991; Winston et al., 1991; Cornelissen et al., 1992; Rolston et al., 1992). Of note, oral
prophylaxis with fluoroquinolones had a significant impact on the development of
infection. All but one of the Gram-negative infections occurred in patients who had not
received prophylaxis with these agents (P = 005). In contrast, clinically documented
infections predominated in patients who had received fluoroquinolones. Whether oral
prophylaxis with fluoroquinolones causes a shift from microbiologically to clinically
documented infections or whether it actually reduces the proportion of febrile episodes
in these patients is an unresolved issue.
The results of the present study showed that monotherapy with cefepime is effective;
overall, the response rate with cefepime alone was 71%. In addition, 26% of primary
infections improved after modification of treatment. These results are comparable with
those obtained with ceftazidime and imipenem-cilastatin monotherapy (Sanders, Powe
& Moore, 1991; Winston et al., 1991; Rolston et al., 1992). The response rates were
excellent for Gram-negative infections, clinically documented infections and fevers of
unexplained origin. On the other hand, only 44% of patients with Gram-positive
infections responded to cefepime monotherapy, although an additional 45% responded
with modification of therapy. In view of the excellent in-vitro activity of cefepime
against Gram-positive bacteria, one might have expected a better response rate for
infections caused by these organisms. However, close analysis of the ten Gram-positive
failures revealed that unfavourable clinical conditions or in-vitro resistance, rather than
a lack of clinical efficacy, accounted for most of these. Three patients died of
Gram-positive infections; two of these were in septic shock when cefepime treatment
was started and died within 24 h. It is unlikely that any antibiotic would have improved
the outcome of patients with such fulminant and often intractable infection. The third
patient died on the seventh day of treatment with irreversible ARDS and
S. pneumoniae bacteraemia. The pneumococcus was highly susceptible to cefepime and
the patient's granulocytopenia had already recovered. Five patients failed therapy
because of catheter-related, coagulase-negative staphylococcal infection. Three of the
strains were methicillin-resistant and vancomycin therapy was required. In the other
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two patients, bacteraemia or fever persisted with cefepime therapy; the catheter was
therefore removed and treatment modified. Subsequent improvement was related more
to removal of the catheter than to modification of therapy. In two patients with
cefepime-susceptible S. mitis bacteraemia, cefepime therapy was discontinued after 3
and 4 days respectively because of the development of ARDS. Similar cases, where
adequate therapy failed to prevent the onset of ARDS, have been reported by others
(EORTC, \99\a,b; Elting, Bodey & Keefe, 1992).
In order to assess both the true response to empirical monotherapy with cefepime, as
well as all subsequent events occurring throughout the period of granulocytopenia,
data were analysed according to three different sets of criteria. Identical results were
obtained with both the EORTC and IHS criteria. Both of these methods focused on the
evaluation of the initial response to empirical therapy. According to the IHS criteria,
responders were classified into two subgroups: those who remained afebrile until
granulocytopenia had resolved (54%) and those who subsequently developed a
secondary infection and who required a modification of empirical therapy (i.e. initial
response but regimen modified) (18%). Analysis of the results according to the criteria
used by Pizzo et al. (1986) showed a survival rate of 96% after resolution of granulo-
cytopenia. Success of therapy (i.e. survival of the patient) was interpreted in the light of
whether or not the empirical therapy was modified. Although this method of assess-
ment allowed us to evaluate the responses for both early (primary) and late (secondary)
infections, the exact response rate to cefepime monotherapy could not, however, be
derived directly from the data. Indeed, relying on only 'success without modification' to
estimate the true response rate would have led to an underestimation, because 16
responders who later developed secondary infections and who required modifications
of therapy (defined as IRBM according to the IHS criteria) were put into the category
'success with modification'. Assessment of the current data according to three different
sets of criteria emphasizes the need to present results in such a way that enables the
efficacy of empirical therapy, the overall response rate and patient survival after the
resolution of granulocytopenia to be evaluated.
In summary, in this open pilot study, cefepime monotherapy was shown to be
effective and safe as empirical treatment of fever in cancer patients with granulocyto-
penia. Whether cefepime is superior to other advanced-generation cephalosporins for
the treatment of infections caused by methicillin-susceptible staphylococci or strepto-
cocci will require evaluation in large, prospective comparative studies.
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